论文部分内容阅读
目的观察替吉奥联合奥沙利铂治疗进展期胃癌的效果与安全性。方法选择进展期胃癌患者46例,随机分为观察组与对照组各23例。对照组予替吉奥治疗,观察组予替吉奥联合奥沙利铂治疗。治疗4个周期后观察、比较2组疗效与不良反应。结果观察组总有效率为43.5%,高于对照组的21.7%(χ~2=4.251,P<0.05);观察组临床获益率为73.9%,高于对照组的39.1%(χ~2=5.231,P<0.05)。2组不良反应主要为骨髓抑制、外周神经毒性及胃肠道反应,不良反应未影响后续治疗。结论替吉奥联合奥沙利铂治疗进展期胃癌临床疗效肯定,且不良反应小,患者耐受性好,值得临床推广应用。
Objective To observe the efficacy and safety of tegafur and oxaliplatin in the treatment of advanced gastric cancer. Methods Forty-six patients with advanced gastric cancer were randomly divided into observation group and control group with 23 cases each. The control group was treated with tegafur and the observation group was treated with tegafur and oxaliplatin. After 4 cycles of treatment, the efficacy and adverse reactions of the 2 groups were observed and compared. Results The total effective rate was 43.5% in the observation group, which was 21.7% higher than that in the control group (χ~2=4.251, P<0.05). The clinical benefit rate in the observation group was 73.9%, which was higher than that of the control group 39.1% (χ~2 = 5.231, P < 0.05). The main adverse reactions in the two groups were myelosuppression, peripheral nerve toxicity and gastrointestinal reactions. Adverse reactions did not affect follow-up treatment. Conclusion The clinical efficacy of teglio combined with oxaliplatin in advanced gastric cancer is positive, and the adverse reactions are small. The patient is well tolerated and worthy of clinical application.